166 related articles for article (PubMed ID: 11078803)
1. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
2. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
3. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
4. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
Langenheim JF; Chen WY
Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
[TBL] [Abstract][Full Text] [Related]
5. A novel design of targeted endocrine and cytokine therapy for breast cancer.
Zhang G; Li W; Holle L; Chen N; Chen WY
Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
[TBL] [Abstract][Full Text] [Related]
6. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.
Chen WY; Ramamoorthy P; Chen N; Sticca R; Wagner TE
Clin Cancer Res; 1999 Nov; 5(11):3583-93. PubMed ID: 10589775
[TBL] [Abstract][Full Text] [Related]
7. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor.
Tsunekawa B; Wada M; Ikeda M; Uchida H; Naito N; Honjo M
Endocrinology; 1999 Sep; 140(9):3909-18. PubMed ID: 10465259
[TBL] [Abstract][Full Text] [Related]
8. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells.
Ramamoorthy P; Sticca R; Wagner TE; Chen WY
Int J Oncol; 2001 Jan; 18(1):25-32. PubMed ID: 11115535
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.
Chen NY; Holle L; Li W; Peirce SK; Beck MT; Chen WY
Int J Oncol; 2002 Apr; 20(4):813-8. PubMed ID: 11894130
[TBL] [Abstract][Full Text] [Related]
10. A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration.
Li R; Yang Y; Lan H; Wang Y; Ge Z; Liu X; Zhou Y; Zhang W; Xian L; Yuan H
Endocrinology; 2023 Nov; 164(12):. PubMed ID: 37934803
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
13. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice.
Peirce SK; Chen WY
Oncogene; 2004 Feb; 23(6):1248-55. PubMed ID: 14647416
[TBL] [Abstract][Full Text] [Related]
14. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5).
Friedrichsen BN; Galsgaard ED; Nielsen JH; Møldrup A
Mol Endocrinol; 2001 Jan; 15(1):136-48. PubMed ID: 11145745
[TBL] [Abstract][Full Text] [Related]
17. Novel reagents for human prolactin research: large-scale preparation and characterization of prolactin receptor extracellular domain, non-pegylated and pegylated prolactin and prolactin receptor antagonist.
Oclon E; Solomon G; Hayouka Z; Salame TM; Goffin V; Gertler A
Protein Eng Des Sel; 2018 Jan; 31(1):7-16. PubMed ID: 29281090
[TBL] [Abstract][Full Text] [Related]
18. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R.
Beck MT; Peirce SK; Chen WY
Oncogene; 2002 Aug; 21(33):5047-55. PubMed ID: 12140755
[TBL] [Abstract][Full Text] [Related]
19. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone.
Shiu RP; Paterson JA
Cancer Res; 1984 Mar; 44(3):1178-86. PubMed ID: 6692402
[TBL] [Abstract][Full Text] [Related]
20. Ovine placental lactogen-induced heterodimerization of ovine growth hormone and prolactin receptors in living cells is demonstrated by fluorescence resonance energy transfer microscopy and leads to prolonged phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT3.
Biener E; Martin C; Daniel N; Frank SJ; Centonze VE; Herman B; Djiane J; Gertler A
Endocrinology; 2003 Aug; 144(8):3532-40. PubMed ID: 12865335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
